Thesis (M.D.)--University of Hong Kong, 1995. / "September 1994." Includes bibliographical references.

Thesis (doctoral)--Katholieke Universiteit te Nijmegen.

Thesis (Ph.D.) - University of Queensland, 2004. / Includes bibliography.

Thesis (M.N.)--Memorial University of Newfoundland, 2003. / Bibliography: leaves 102-114. Also available online.

Thesis (M.Sc.)--Memorial University of Newfoundland, 2004. / Bibliography: leaves 150-174.

Thesis (M.D.)--University of Hong Kong, 1995. / "September 1994". Includes bibliographical references. Also available in print.

Thesis (Ph. D.)--Virginia Commonwealth University, 2006. / Prepared for: Dept. of Microbiology and Immunology. Bibliography: leaves 134-165.

Thesis (Ph. D.)--West Virginia University, 2001. / Title from document title page. Document formatted into pages; contains xiv, 150 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references (p. 104-120).

Thesis (MTech (Biomedical Technology))--Cape Peninsula University of Technology, 2011 / Introduction: A prospective study was conducted across the spectrum of cervical aberrancies with the aim of assessing the distribution of HPV relating to the degree of cervical abnormalities using polymerase chain reaction (PCR) and P16INK4A assay as a marker for cervical disease progression. Patient demographics including their sexual, contraceptive and screening history were evaluated to determine whether subsidiary risk factors contribute towards the development of cervical lesions among Namibian women. Methods: From Feb 2006 to March 2007, 187 women with abnormal cervical cytology were examined. Cervical smears were immunostained using the P16INK4A assay (Dakocytomation, Heidelberg, Germany). Brown discolourisation of the nucleus and/or cytoplasm of abnormal cells were considered positive for P16 immunoexpression. Absence of brown decolourisation in the nucleus or cytoplasm of abnormal cells was considered negative for P16 immunoexpression. DNA was successfully extracted from 182 specimens, and the respective samples were subjected to PCR using GP5+/6+ primers. Type-specific (HPV types 16 and 18) PCR were also applied. Patients’ sociodemographics, sexual and reproductive history, HIV status, contraceptive use and Pap smear history were all recorded.

Thesis (MTech (Radiography))--Cape Peninsula University of Technology, 2012 / Introduction: Brachytherapy plays an essential role in the management of patients with cervical cancer. The high cervical cancer burden in Africa presents challenges with regard to provision and sustainability of these services. This study analysed treatment outcomes of two brachytherapy modalities, high dose rate (HDR) and low dose rate (LDR) intracavitary treatment for patients with cervical cancer, and evaluated the problems and challenges of the provision of these services within the African context. Methodology: The study was conducted using a case study approach with mixed methods at two sites in Africa, one in South Africa (Centre I) and the other in Kenya (Centre II). The study explored factors and issues affecting definitive radiotherapy of the patient with cervical cancer at the two sites with a focus on the brachytherapy treatment. The case study provided an opportunity to collect in-depth data consisting of quantitative and qualitative components that generated numeric and textual data. Treatment outcomes of one site treating with HDR and the other LDR intracavitary brachytherapy were retrospectively analysed for a maximum sample size of 193 (91%) patients in the HDR group and 49 (100%) patients in the LDR group. All patients were treated with external beam radiation therapy (EBRT) using parallel opposed beams (POP) for the patients that received LDR brachytherapy, and four field box technique or POP for those that received HDR brachytherapy. The linear quadratic formula was used to calculate the equivalent dose in 2 Gy fractions (EQD2) between the two groups.